Logo
    Search

    Podcast Summary

    • Understanding Psychopharmacology: Impact of Medications on Brain FunctionPsychopharmacology involves studying medications and substances that affect brain function, treating disorders like mood, cognitive, and behavioral disturbances, and recognizing the importance of receptor interactions.

      Psychopharmacology is a subfield of psychiatry dealing with medications and substances that impact brain function, both positively and negatively. Psychopharmacology agents, or medications, are used to treat mental disorders primarily characterized by mood, cognitive, and behavioral disturbances. These medications' effectiveness depends on their intended use. For instance, valproic acid, which treats seizures, isn't considered a psychotherapeutic agent for bipolar mood disorder. Caffeine, an adenosine receptor antagonist, can be considered a psychiatric medication as it alters brain function, making people more awake. Historically, people consumed fermented beverages like beer or wine for safety reasons, but coffee's stimulating effects increased productivity. Overall, understanding the basics of psychopharmacology and how medications bind to receptors is crucial for mental health professionals to effectively treat various mental disorders.

    • Understanding Medication Absorption, Distribution, and MetabolismGastric bypass surgeries impact medication absorption, with longer absorption meds like Olanzapine being affected. The liver, with enzymes like cytochrome P450, plays a crucial role in medication metabolism, essential for processing both toxins and psychiatric meds.

      The absorption, distribution, and metabolism of medications are crucial factors in determining their therapeutic effects. Many pathogens in contaminated water can cause illness, but when it comes to psychopharmacology, understanding these processes is vital. For instance, gastric bypass surgeries like Roux en Y can significantly impact medication absorption by reducing the surface area available for absorption. This is particularly relevant for medications with longer absorption times, such as Olanzapine. On the other hand, rapid absorption medications like lorazepam are unaffected by such surgeries. The liver plays a significant role in medication metabolism, with enzymes like cytochrome P450 breaking down both toxins and medications. These enzymes have evolved to combat plant toxins, making them essential for processing psychiatric medications as well. Overall, recognizing the impact of absorption, distribution, and metabolism on medication efficacy is essential for optimizing treatment outcomes.

    • Liver enzymes play a crucial role in psychiatric medication metabolismSpecific liver enzymes like 2d6, 1a2, and 3a4 impact medication metabolism. A lack or blockage of 2d6 can lead to increased medication levels, side effects, and toxicity.

      Certain liver enzymes, specifically 2d6, 1a2, and 3a4, play a crucial role in the metabolism of psychiatric medications. 2d6 is the most common enzyme involved and is responsible for breaking down many tricyclic antidepressants. A lack of this enzyme or the presence of a medication that blocks it can lead to increased medication levels, resulting in side effects or toxicity. For instance, taking amitriptyline and a 2d6 blocker like ketoconazole can increase amitriptyline levels by 5 to 10 times, leading to confusion, memory problems, and even toxicity. Pharmacologists must consider potential drug-drug interactions and whether a medication will induce or inhibit the metabolism of a specific drug, as this can significantly impact the effectiveness and safety of treatment.

    • Drug interactions in psychiatry impacting medication levelsCareful monitoring and gradual adjustment of drug dosages in psychiatry are crucial to minimize adverse effects. While resources exist to identify potential drug interactions, measuring plasma concentrations may provide a more definitive answer.

      Certain drugs, particularly those used in psychiatry, can significantly impact plasma concentrations of other medications due to their effects on liver enzymes. This can lead to therapeutic failure or unwanted side effects. While there are resources available to help identify potential drug interactions, the accuracy of these tools can vary. Measuring plasma concentrations of medications can provide a more definitive answer, but it may not always be necessary. In some cases, adjusting the dosage based on side effects or symptoms can be an effective approach. It's also important to note that rapid titration of medications can contribute to side effects. Therefore, careful monitoring and gradual adjustment of dosages are crucial to minimize adverse effects.

    • Pressure to discharge patients quickly can lead to unwanted side effects from medications, but giving receptors time to adapt can minimize these side effects.Slowing down medication titration can help minimize side effects and improve overall treatment outcomes by allowing receptors time to adapt to medications.

      Hospitals are under pressure to discharge patients sooner, leading to quicker medication titration, which can result in unwanted side effects. However, giving these receptors time to adapt to medications can eliminate or minimize these side effects. For instance, a study conducted by UCLA using imipramine, a tricyclic antidepressant, demonstrated that a slower titration schedule resulted in zero side effects despite reaching the same blood level as the standard titration. This shows that rushing the medication process may not always be the best way to avoid side effects. Most psychiatric drugs work by binding to receptor sites on the surface of neurons in the brain. They can act as antagonists, blocking the receptor, or agonists, working in the same direction as the neurotransmitter. Additionally, drugs can block the reuptake of certain neurotransmitters, allowing them to remain in the synaptic cleft for longer periods, increasing their availability to the postsynaptic cell. Understanding how these drugs work and giving them time to take effect can help minimize side effects and improve overall treatment outcomes.

    • Two types of psychoactive drugs: immediate and long-term actingImmediate drugs like Benzodiazepines and alcohol change receptors, while long-term drugs like SSRI antidepressants change neural circuits, and psychotherapy acts as a form of repetitive perturbation on a longer timescale, with long-term effects ultimately being more lasting.

      There are two main categories of psychoactive drugs: those that produce immediate effects by altering ion flow into and out of nerve cells, such as Benzodiazepines and alcohol, and those that work through a process of initiation and adaptation, like SSRI antidepressants, which increase serotonin and eventually lead to a decrease in receptors and changes in second messenger molecules and even DNA transcription, taking weeks to produce noticeable effects. The immediate drugs act by changing the physical state of receptors, while the longer-acting drugs change the function of entire neural circuits. Psychotherapy, too, can be seen as a form of repetitive perturbation of brain circuits, making it similar to medication but with a longer timescale. This was demonstrated in an experiment where people with obsessive-compulsive disorder were treated with either behavioral response prevention therapy or fluoxetine, both for six weeks. While the immediate relief from behavioral therapy was noticeable right away, the long-term changes brought about by the medication took longer to manifest but ultimately led to more lasting effects.

    • Behavior therapy and Prozac alter OCD circuit, but behavior therapy lasts longerBehavior therapy and medication have similar biological effects on OCD, but behavior therapy's benefits persist while medication's fade, and antidepressants can cause epigenetic changes for depression, but long-term use depends on individual's depression history

      In a study on Obsessive Compulsive Disorder (OCD), both behavior therapy and Prozac showed similar biological effects by altering the circuit involved in OCD and improving the negative feedback loop. However, the behavior therapy had longer-lasting effects as people learned to apply it at home, while medication's effect wore off once it was discontinued. For depression, antidepressants can cause epigenetic changes to help treat the condition, but the duration of medication use depends on the individual's history of episodes. Those with a single episode may no longer need medication after remission, while those with recurrent major depression often require long-term use due to an underlying genetic vulnerability. The risk of future episodes increases with each occurrence. Treating depression is akin to managing type 1 diabetes mellitus, where normalizing symptoms doesn't eliminate the underlying condition.

    • Chronic and relapsing psychiatric illnesses require ongoing medicationMany psychiatric conditions are chronic and relapse if medication is discontinued, making ongoing treatment essential for managing symptoms and preventing relapse.

      Many psychiatric illnesses, such as major depression, bipolar mood disorder, obsessive compulsive disorder, and psychotic disorders, are chronic and relapsing. Current medications only alleviate or control symptoms, but don't cure the underlying genetic abnormalities. Discontinuing medication increases the risk of relapse, and each relapse makes the illness more resistant to treatment. For mild cases or those with dysphoric symptoms, lifestyle changes and therapy can be beneficial. However, for severe cases with neurovegetative symptoms, medication is necessary to improve the person's condition and enable them to benefit from other treatments. It's important to educate patients about the chronic nature of these illnesses and the potential for relapse if they discontinue medication.

    • Depression's Complex Nature: Beyond SerotoninDepression involves multiple neurotransmitters and systems, including serotonin, norepinephrine, GABA, and inflammation. Antidepressants can provide an artificial boost to modulatory systems.

      Depression is a complex condition that cannot be fully explained by a single neurotransmitter like serotonin. The limbic system, which is involved in mood regulation, is modulated by several neurotransmitters including serotonin, norepinephrine, and GABA. Depression may not respond adequately to treatment that focuses on just one neurotransmitter, especially in severe cases. Additionally, inflammation is also believed to play a role in depression and other mental health conditions. The immune system produces cytokines, which can alter neuronal functioning and contribute to feelings of dysphoria and malaise. The idea that there is no such thing as a serotonin deficiency in depression is technically correct, but the limbic system in depression may be failing beyond the ability of neurotransmitters like serotonin to adequately modulate. Antidepressants can be seen as giving the modulatory systems an artificial boost. A meta-analysis of antidepressant studies, including unpublished data, found a low effect size for antidepressants, but it's important to note that the study had its limitations and the debate around the effectiveness of antidepressants continues.

    • High placebo response rates challenge antidepressant efficacyAntidepressant trials overreport response due to high placebo effect. True efficacy is difficult to determine without a control group.

      The effectiveness of antidepressants may be overestimated due to high placebo response rates. According to Dr. Cummings, if we define response as a 50% reduction in depressive signs and symptoms, antidepressant trials report around a 60-65% response rate. However, when looking at remission, where patients are free of depressive signs and symptoms, the number drops to around a third. The placebo effect is often more significant in studies where attention and social interaction are lacking, such as in antidepressant trials. These factors contribute to the high placebo response rate, making it challenging to determine the true efficacy of antidepressants. It's crucial to have a control group in clinical trials to accurately assess the impact of the treatment. In the next session, we will discuss antipsychotics, their history, mechanisms of action, and conditions they've shown benefit for, as well as their risks.

    Recent Episodes from Psychiatry & Psychotherapy Podcast

    Reflective Functioning: The Key to Attachment with Dr. Howard Steele

    Reflective Functioning: The Key to Attachment with Dr. Howard Steele

    In this episode, we discuss “reflective function,” which is a precursor to the concept of mentalization. Reflective function is best understood not as synonymous with mentalization, but as a scale from -1 to 9, based off certain adult attachment interview questions that measure the person’s ability to describe their own and others’ internal states, motivations, and articulate a nuanced and unique understanding of life from 0 to 12 years old. This scale was developed by attachment researchers at the University of London, including Dr. Howard Steele and Dr. Peter Fonagy.

    Bruce Perry on the Healing Power of Human Connection and Resilience in Trauma

    Bruce Perry on the Healing Power of Human Connection and Resilience in Trauma

    In today’s episode, we talk with Dr. Bruce Perry who co-authored, The Boy Who Was Raised As A Dog, Born For Love: Why Empathy is Essential and Endangered, and What Happened to You? Conversations on Trauma, Resilience, and Healing (2021). We are also joined by Megan White Zappitelli, M.D., a child and adolescent psychiatrist, and Maddison Hussey, M.D., a child and adolescent fellow. 

    Early Psychosis: Detection and Treatment

    Early Psychosis: Detection and Treatment

    In this episode, we are joined by a panel of experts to discuss treatment of psychosis. Experiences of psychosis are common. When these experiences lead to interference in achieving life goals and/or distress, individuals can benefit from seeking evidenced-based care. The earlier individuals experiencing psychosis come to treatment, the better the outcomes. We are all allies in connecting these young people to care and services. Recovery is possible—people living with psychosis experiences can lead full, meaningful, and fulfilling lives. 

    Q&A with Dr. Michael Cummings

    Q&A with Dr. Michael Cummings

    In this episode, we welcome back fan favorite Dr. Michael Cummings and ask questions sent in by listeners. Topics include Schizophrenia, Social Media Trends, and the SSRI controversy. We are thrilled to dedicate an episode that allows individuals to ask pointed questions and glean from Dr. Cummings' expertise. 

    What People Want From Therapy with Linda Michaels

    What People Want From Therapy with Linda Michaels

    Therapies of depth, insight, and relationship have been missing from, if not pushed out of, the public conversation on mental health treatment. After decades of attack from multiple fronts, these therapies are misunderstood, undervalued, and overlooked by the general public. In order to address this challenge and change this trajectory, we must start by listening to the public and understand their needs, values, and preferences about therapy. Dr. Linda Michaels and colleagues conducted an extensive research project, leveraging qualitative and quantitative tools and techniques widely used in the corporate world, focused on “listening” to the public and understanding what people want and need from therapy. 

    Linda Michaels, PsyD, MBA, is a clinical psychologist in private practice in Chicago. She is also chair and co-founder of the Psychotherapy Action Network (PsiAN), a non-profit that advocates for quality therapy. 

    Link to blog here.

    5 Factors and Domains of Psychiatric Care

    5 Factors and Domains of Psychiatric Care

    In this Episode, Dr. David Puder, Dr. Adam Borecky, and Joanie Burns discuss the 5-factor approach to holistic, patient-centered psychiatric care. This approach takes into account that each individual who seeks care is unique in their physiological and psychological make-up and that multiple factors influence both physical and mental health (for better or worse). 

    The 5-factor approach to treatment is based on the importance of sensorium and its pivotal role in regulating thoughts, feelings, and overall mental health. Sensorium is a lens to understand how we focus on various things. Sensorium is total brain function, which fluctuates throughout the day and depends on a number of factors, including sleep, stress levels, and more.

    Mentalization Based Therapy (MBT), with Dr. Anthony W. Bateman, MA, FRCPSYCH and Dr. Peter Fonagy, Ph.D., FBA

    Mentalization Based Therapy (MBT), with Dr. Anthony W. Bateman, MA, FRCPSYCH and Dr. Peter Fonagy, Ph.D., FBA

    In this episode, we are joined by Dr. Anthony W. Bateman and Dr. Peter Fonagy to discuss their expertise on Mentalization. 

    Mentalization refers to the capacity to reflect upon and understand one's own state of mind and the states of mind of others.  This involves recognizing and making sense of one's own and others’ emotions, beliefs, needs and desires.  People use this tool consciously and unconsciously to make sense of others and themselves. Often done automatically, a person may form beliefs about the people they interact with, making assumptions about their mental states. These beliefs tend to have a strong influence on the mental state of the person, whether or not they are correct.

     

    Beginning the Treatment with Jonathan Shedler, PhD

    Beginning the Treatment with Jonathan Shedler, PhD

    Dr. Jonathan Shedler is well known for his work on the efficacy of psychodynamic therapy. He has highlighted the importance of the initial phase of therapy in establishing a foundation for successful treatment. Dr. Shedler strongly believes the consultation phase is crucial to developing a working alliance between client and therapist and building a treatment frame and structure. Without this foundation, there is no mutual understanding about the goal or the purpose of treatment, and psychotherapy should not move forward. Join us in this episode as Dr. Shelder discusses how to create a firm starting foundation in clinical practice.

    Adverse Childhood Experiences Part 2: Measurement, Impact on Future Mental Health, Dissociation, and Timing of Trauma

    Adverse Childhood Experiences Part 2: Measurement, Impact on Future Mental Health, Dissociation, and Timing of Trauma

    In this week’s episode of the podcast, we will continue our discussion regarding adverse childhood experiences (ACEs) and their influence on the development of future mental health disorders. The greatest predictive factor of the relationship between ACEs and future mental health disorders has to do with the severity, duration, and number of traumatic events. We’ll explore the Childhood Trauma Questionnaire and the data of how ACEs increase the risk of certain personality disorders and psychiatric conditions.

    Link to blog: 

    https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/episode-204-adverse-childhood-experiences-part-2-measurement-impact-on-future-mental-health-dissociation-and-timing-of-trauma

    Related Episodes

    Does Cannabis Use Increase Schizophrenia and Psychosis?

    Does Cannabis Use Increase Schizophrenia and Psychosis?

    In this episode, David Puder, M.D., and Victoria Agee discuss possible links between marijuana use and psychosis. There a multiple studies which reveal links in genetics and marijuana potency that can lead to an increase in schizophrenia and psychosis. 

     

    Link to resource library

    How To Pick A Good Therapist

    How To Pick A Good Therapist

    Working with a good therapist often requires fewer sessions than other therapists to see improvement; in contrast, working with a therapist you don’t connect with, or with inadequate training, may require an extended number of sessions (Okiishi et al. 2003).  People that see effective therapists are more likely to recover or partially recover, whereas those that work with a “bad” therapist are more likely to see no change or an increase in symptoms (Okiishi et al. 2006). 

     Link to full article/blog

     

    Catatonia: Diagnosis and Treatment

    Catatonia: Diagnosis and Treatment

    Catatonia is a severe motor syndrome. It is a secondary response to an underlying illness that requires quick diagnosis and treatment. There are many different things that lead to catatonia, so finding out the underlying cause is very important. In this episode, Dr. Cummings and I discuss the history, diagnosis, and treatment of catatonia. 

    Link to resource library.

    Link to Blog.

    Ketamine and Psychedelics with Dr. Michael Cummings

    Ketamine and Psychedelics with Dr. Michael Cummings

    On this week’s episode of the podcast, I interview Dr. Cummings, a reputable psychopharmacologist, about ketamine. We talk about psychedelics, the research behind it, both the positives and the negatives. We will look at how it is or is not helpful in psychiatric treatments.

     

    (Disclaimer: There are no conflicts of interest to report. Neither Dr. Puder or Cummings is affiliated with any companies in favor of ketamine and other drug companies.)

    Ketamine

    Although ketamine has recently become a medication of great interest in psychiatry, it actually is a fairly old medication. It was first synthesized in 1962 and began human trials for anesthesia in 1964. It was finally approved by the FDA as a dissociative anesthetic in 1970.

    What has piqued interest in psychiatry is that infusion of a smaller dose of ketamine produces a rapid response in terms of reversal of depressed mood, suicidality, and some treatment-resistant depressed patients.

    The literature is rich (in one sense) as the most recent consensus statement (Sanacora, 2017) looked at seven randomized controlled trials, all of which support a robust antidepressant response and anti-suicide response. The difficulty with those trials is the majority of them lasted only one week. A few of the later trials lasted two to three weeks with two to three infusions per week. So, what’s lacking at this point is adequate data regarding long term treatment response and data about transitions to more traditional antidepressant treatments.

    For the rest of the blog that goes with this episode, go: here

    Instagram: dr.davidpuder

    Twitter: @DavidPuder

    Facebook: DrDavidPuder